261 related articles for article (PubMed ID: 33126605)
21. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
22. CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses.
Mei D; Luo Y; Wang Y; Gong J
Cancer Imaging; 2018 Dec; 18(1):52. PubMed ID: 30547844
[TBL] [Abstract][Full Text] [Related]
23. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
24. Roles of highly expressed PAICS in lung adenocarcinoma.
Zhou S; Yan Y; Chen X; Wang X; Zeng S; Qian L; Wei J; Yang X; Zhou Y; Gong Z; Xu Z
Gene; 2019 Apr; 692():1-8. PubMed ID: 30641222
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.
Li R; Li Q; Lin S; Li W; Yu L; Wang L; Dong X; Yu L; Li S; Liu W; Li B
Clin Transl Oncol; 2019 Mar; 21(3):298-303. PubMed ID: 30022385
[TBL] [Abstract][Full Text] [Related]
26. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
[TBL] [Abstract][Full Text] [Related]
27.
Li JP; Hsieh MJ; Chou YE; Chao YH; Tsao TC; Yang SF
Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32344833
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic characteristics and EGFR mutations in lung cancer patients aged below 45 years.
Xia J; Li H; Ji Y; Mi C; Chen G; Li P; Zhang R; Chen W; Wang J
Curr Probl Cancer; 2019 Aug; 43(4):363-370. PubMed ID: 30522775
[TBL] [Abstract][Full Text] [Related]
29. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
30. Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients.
Ali Beg MM; Fahdil SR; Yadav P; Shukla KK; Mohan A; Saxena A
Asian Pac J Cancer Prev; 2019 Mar; 20(3):825-830. PubMed ID: 30912007
[TBL] [Abstract][Full Text] [Related]
31. EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del/L858R mutations.
Xia L; Wang H; Xiao H; Lan B; Liu J; Yang Z
Thorac Cancer; 2020 Oct; 11(10):2755-2766. PubMed ID: 32881299
[TBL] [Abstract][Full Text] [Related]
32. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
33. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
[TBL] [Abstract][Full Text] [Related]
34. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
[TBL] [Abstract][Full Text] [Related]
35. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
36. Correlation of E-cadherin gene polymorphisms and epidermal growth factor receptor mutation in lung adenocarcinoma.
Huang CY; Hsieh MJ; Liu TC; Chiang WL; Liu MC; Yang SF; Tsao TC
Int J Med Sci; 2018; 15(8):765-770. PubMed ID: 30008585
[TBL] [Abstract][Full Text] [Related]
37. Effect of WW Domain-Containing Oxidoreductase Gene Polymorphism on Clinicopathological Characteristics of Patients with EGFR Mutant Lung Adenocarcinoma in Taiwan.
Li JP; Chang JT; Ju PC; Hsieh MH; Chao YH; Tsao TC; Hsieh MJ; Yang SF
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948746
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of localization of epidermal growth factor receptor in lung adenocarcinoma.
Wang JL; Fang CL; Tzeng YT; Hsu HL; Lin SE; Yu MC; Bai KJ; Wang LS; Liu HE
J Biomed Sci; 2018 Jun; 25(1):53. PubMed ID: 29950164
[TBL] [Abstract][Full Text] [Related]
39. Association of cytokines levels with epidermal growth factor receptor mutation in lung cancer patients.
Gaur P; Bhattacharya S; Kant S; Kushwaha RAS; Singh G; Pandey S
J Cancer Res Ther; 2020; 16(4):811-815. PubMed ID: 32930123
[TBL] [Abstract][Full Text] [Related]
40. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.
Ono A; Kenmotsu H; Watanabe M; Serizawa M; Mori K; Imai H; Taira T; Naito T; Murakami H; Nakajima T; Ohde Y; Endo M; Yamamoto N; Koh Y; Takahashi T
Ann Oncol; 2014 Oct; 25(10):1948-1953. PubMed ID: 25009007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
